Perhaps it is easy to sneer at aging investment bankers tottering down to the doctor to get juiced. Consider, though, the case of a trans man who wants the biochemistry he feels to match his gender identity. In both cases, in the traditional way of thinking about medicine, doctors would have to label the men diseased before they could receive the drug that allows them to change in the desired ways. And if there is a logic to supporting the trans man in his quest for bodily autonomy, should the same reasoning extend to everyone else?

These are not merely abstract, philosophical questions. What’s at stake is not only the ethical future of the medical community, but the boundaries of a human life.